Purpose: This literature review was conducted to evaluate the quality of current evidence of clinical performance provided by American Dental Association-certified dental implant manufacturers and manufacturers with strong market penetration in the United States. The study also compared the clinical performance of different dental implant systems.
Materials And Methods: A letter was sent to 6 implant manufacturers requesting 10 references each that validated the manufacturer's implant system in a variety of clinical applications. References were reviewed and classified relative to strength of evidence. Data extraction was then performed. Comparisons of implant survival data from 5-year studies were made, and data were pooled to establish an overall 5-year survival rate with confidence intervals (CIs).
Results: A total of 69 references were provided by the 6 implant manufacturers (Astra Tech, Centerpulse, Dentsply/Friadent, Implant Innovations, Nobel Biocare, and Straumann) but only 59 articles were available for review. Of those references, most were level-4 (case series) or level-5 (expert opinion) articles. Five-year survival data were extracted from 17 articles demonstrating overlap of CIs from the weighted average of the pooled data from each specific manufacturer; substantial equivalence of all implant systems was demonstrated based upon survival alone at 5 years. When all data were pooled, the 5-year survival rate of 96% (CI: 93% to 98%) was observed for a total of 7,398 implants.
Discussion: No obvious differences in implant survival were observed when comparing implant systems.
Conclusions: The evidence supporting implant therapy is generally derived from level-4 case series rather than higher-level cohort or controlled clinical trials. Articles that directly compared different implant systems were not found. Five-year implant survival rates easily exceeded the minimums recommended by the American Dental Association certification program. (More than 50 references.)
Download full-text PDF |
Source |
---|
Int J Oral Maxillofac Implants
January 2025
Purpose: This retrospective clinical study aims to analyze single-unit implant-supported restorations' clinical and radiographic outcomes comprehensively.
Materials And Methods: In this retrospective study, patients who had undergone 12 months of implant-supported singleunit fixed prosthetic treatment were scanned from the archives, and a hundred patients were included in the study. Implant success and survival rates were assessed according to the consensus decisions published at the International Oral Implantology Congress in 2007.
Int J Oral Maxillofac Implants
January 2025
Purpose: Implant stability (IS) is crucial to the success of any implant-based therapy. The present work aimed to determine the relationship between primary and secondary stability and a range of variables.
Material And Methods: This retrospective cohort study included a total of 169 patients, who received 445 dental implants.
Int J Oral Maxillofac Implants
January 2025
Purpose: The available scientific evidence on the effectiveness of the surgical treatment of peri-implantitis is limited. The aim of this study was to assess the risk of recurrence or disease progression in patients with peri-implantitis that underwent surgical treatment.
Materials And Methods: A retrospective cohort study was carried out in patients subjected to peri-implant surgery between 2015 and 2021, and with a minimum follow-up of 12 months.
Adv Sci (Weinh)
January 2025
Department of Orthopaedics, The First Affiliated Hospital of Nanjing Medical University, Jiangsu, 210029, China.
Patellar dysplasia (PD) can cause patellar dislocation and subsequent osteoarthritis (OA) development. Herein, a novel ABCA6 mutation contributing to a four-generation family with familiar patellar dysplasia (FPD) is identified. In this study, whole exome sequencing (WES) and genetic linkage analysis across a four-generation lineage presenting with six cases of FPD are conducted.
View Article and Find Full Text PDFJ Bone Joint Surg Am
January 2025
Department of Orthopaedic Surgery, Children Hospital, National Taiwan University Hospital, Taipei, Taiwan.
Background: Reoperation is a major adverse event following surgical treatment but has yet to be used as a primary outcome measure in population studies to assess current treatments for developmental dysplasia of the hip (DDH). The purpose of the present study was to explore the risk factors associated with reoperations following procedures under anesthesia ("operations") for DDH in patients between the ages of 1 and 3.00 years, with the goal of deriving treatment recommendations.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!